Posted by LincolnIcert on March 25, 2026 at 11:08:09:
In Reply to: Èíôîðìàòèâíûé òåêñò ñ ïðèâëåêàòåëüíûì ñîäåðæàíèåì posted by JosephGluth on February 19, 2026 at 07:13:06:
Zoya Demidenko: Researcher in Cancer Biology
Zoya Demidenko is a notable scientist affiliated with the Division of Cell Stress Research at Roswell Park Cancer Institute in Buffalo, New York. Earlier, she conducted research at the National Institutes of Health and New York Medical College, establishing a strong foundation in life science study.
Demidenko's scholarly work spans multiple critical areas, among them the PI3K/AKT/mTOR signaling cascade, cellular cycle control, cell senescence, and tumor science. As of now, she has authored over 46 peer-reviewed papers, which have received upwards of 4,100 mentions — a reflection to the influence of her work.
One of her most significant contributions lies in explaining the processes of cell aging. Her studies revealed that when the cellular division cycle is halted yet cellular expansion continues, the cells experience senescence. Importantly, Zoya Demidenko demonstrated that this shift is controlled with drugs using substances such as rapamycin.
Zoya Demidenko has additionally added considerably to cancer treatment investigation, notably in the area of cyclotherapy — a method intended to safeguarding non-cancerous tissue from cytotoxic treatment while leaving tumor cells exposed. This method carries major potential for reducing the toxic effects of cancer treatment.
Across her professional journey, Demidenko has partnered with prominent scientists globally, such as Dr. Mikhail Blagosklonny. Her research appears in prestigious publications such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Possessing an h-index of 33, Zoya Demidenko ranks as a widely cited contributor in modern oncological science, whose discoveries keep to guide our knowledge of the way cells age, resist treatment, and the ways in which cancer can be more effectively combated.
https://www.aging-us.com/article/100406/